The emphasis in multiple sclerosis (MS) management has more recently been placed on the development and use of disease-modifying treatment (DMT) to reduce clinical and radiological disease activity and improve long-term outcomes. In this respect we, the MS community, have benefited from a high level of sustained investment from Big Pharma -without such interest we would not have gained such a range of treatment options for relapsing remitting MS (RRMS) in oral, injection and infusion form. For this we should be thankful.
As MS clinicians and researchers, we do not underestimate the symptom burden experienced by patients on a frequent or daily basis, or the impact such symptoms have on quality of life. Many symptoms remain inadequately treated, with the available drug options quickly exhausted, due to incomplete efficacy or intolerance of current drug choices. We agree with the 'Workshop on Research in Multiple Sclerosis (2001)', which stated that 'improvement and validation of therapeutic approaches to symptom management has received relatively scant scientific attention'. 1 The recommendations of this group, therefore, included the pursuit of 'new, more effective therapeutic approaches' and that 'better strategies should be developed to extract the maximum possible scientific value from MS clinical trials'. 1 Should we turn to Big Pharma to invest in future trials for symptomatic therapies? Not this time. We need to remember that the goal of Big Pharma is divergent from our own. We aim to eliminate clinical and radiological evidence of disease activity in RRMS, to prevent or at least delay progression of MS, to eliminate or at least minimize all MS-related symptoms and to provide a quality of life for all people with MS which is equal to that of their peers. Our ultimate goal is to cure MS. Big Pharma's primary goal is to make a profit -MS, as a common chronic neurological disease without cure, will always be seen as a profitable venture. It has invested in novel therapies that can reduce clinical and radiological relapses, but do not significantly delay progression or offer a cure; therapies that can be prescribed exclusively in patented form typically for 12-15 years; therapies with a not insignificant cost.
Is it in the interest of Big Pharma to repurpose drugs off-patent or with a short patent? Unfortunately not. Such trials may not be viewed by Big Pharma as financially astute endeavours and, therefore, are less likely to attract investment. In this respect, Big Pharma has already influenced trials performed in RRMS and secondary progressive MS (SPMS). There is good evidence in phase I and II trials that intravenous rituximab, a chimeric anti-CD20 monoclonal antibody, significantly reduces clinical relapses and MRI activity in RRMS. 2, 3 However, a phase III trial was never performed; the company involved reported high levels of anti-rituximab antibodies and thus developed a humanized form of anti-CD20, ocrelizumab. The duration of the patent for ocrelizumab will, therefore, be favourable, in comparison to the expiration of that for rituximab in 2015. For the company with exclusive rights to rituximab, this timeframe may have been considered too short to be a worthwhile venture; for the scientific community, it has restricted any further studies until the drug reaches off-patent status.
Another example is the MS-STAT phase II trial performed by Chataway et al. 4 This double-blind controlled trial of high dose oral simvastatin in people with SPMS identified a significant reduction in annualized rate of brain atrophy in the treatment group, with a good tolerability and safety profile. This trial was performed without contribution from Big Pharma; simvastatin has been off patent since 2006 and was, therefore, not considered a lucrative venture. Clearly, phase III trials need to be performed, but it is not in the interest of any pharmaceutical company to fund such a trial. Who will fund the licensing of such a drug in SPMS? Again, this is not likely to feature in the projects of Big Pharma.
As clinicians and researchers in MS we perform original research, with the aim of publishing this work to disseminate knowledge. It is equally as important to report negative findings or unexpected side-effects, as it is to publish positive results or good tolerability and safety profiles. Any novel work, particularly when involving potential new therapies, is worth reporting to the wider MS community. It is well recognized that published studies performed by Big Pharma are more likely to report positive results than those funded by government or non-profit organizations across phase I, II and III trials. Bourgeois et al. 5 reviewed 546 drug trials conducted between 2000 and 2006, listed on ClinicalTrials.gov, across five major drug groups (anticholesteremics, antidepressants, antipsychotics, proton pump inhibitors and vasodilators). By 2010, two thirds of these studies had published results. Of trials performed by Big Pharma, 85% reported positive outcomes, compared to 50% of government-funded trials and 72% of non-profit organizations. 5 Although there are potential biases with studies performed by Big Pharma, this also suggests that the pharmaceutical industry is less likely to publish results of studies that do not endorse its drugs. This is a reason in itself to exclude Big Pharma from trials of symptomatic therapies -we are as likely to discover therapies with no or little benefit as often as those with good effects along this path. This information needs to be shared quickly so that we, as a community, can move on.
In summary, we need to utilize our skills as clinicians to design and lead clinical trials in order to provide clinically relevant data on new and existing drugs. We will continue to rely on Big Pharma to invest in the preliminary stages of development of novel therapies, particularly in RRMS. However, we must take the reins when it comes to the execution of clinical trials and the scrutiny of therapies for symptom management. We must consider new, old and the repurposing of drugs. We must find new funding avenues for clinical trials and licensing of drugs off-patent. The MS community will be reassured by, and grateful for, our endeavours. Should Big Pharma do more with regards to symptomatic therapy in MS? No, we should.
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Symptomatic therapy in multiple sclerosis: Big pharma should do more -YES Aksel Siva and Orhun Kantarci
Multiple sclerosis (MS) has a wide variety of clinical phenotypes. This can range from asymptomatic to relapsing-remitting to progressive disease phases as well as an overlapping period in between each of these phases. Each phase can further be classified as being active or not active. 1 It is well known that patients may remain in each type indefinitely or for a variable period before progressing to the next clinical phenotype.
Patients may develop residual neurological deficits either from the very beginning or later at any time during the course of the disease. Although a benign course may be seen in up to one-quarter of patients, even these may have some mild motor or sensory symptoms that may cause some discomfort, fatigue that may interfere with their daily living activities or cognitive changes leading to some limitations in their professional life.
Most MS patients will end up having some residual neurological symptoms. Although the residual symptoms correlate with some disability steps in MS, this may not always be the case. For example, people without significant motor findings may also have other symptoms that, once properly managed, will ease that individual's life. However, despite the large proportion of patients affected with a wide variety of neurologic symptoms, the number of available symptomatic treatments is limited and they are only partially effective. It is clear that some of these MS-related symptoms are not MS specific and may be seen as a result of other neurological (and non-neurological) disorders resulting in a much larger patient population that requires such therapies. Regarding the available symptomatic therapies and their efficacies, it becomes clear that this is a neglected area with a high need of new therapies.
The emphasis in MS has almost always been on large trials to slow or eliminate the disability worsening by eliminating relapses or shortening the time to recovery after relapses. However, many patients still have residual symptoms after a relapse and continue to develop progressive symptoms despite the available treatments. Currently, there are 12 approved disease-modifying long-term therapies in MS; some others are expected to be approved soon and many more are in clinical trials. However, none offers a cure, but rather reduce clinical relapses and magnetic resonance imaging (MRI) burden to a certain extent, with a less pronounced effect on long-term disability. These therapies continue to be effective in responders as long as they are used, but in some their efficacy may wear off over time. The higherefficacy disease-modifying therapies are also associated with more serious adverse events. So, it is clear that new treatments are needed for better long-term management of a progressive disease such as MS. The good news is that there are a large number of ongoing trials in this area, most sponsored by the pharmaceutical industry.
A current search for MS treatment on www.clinicaltrials.gov reveals that there are 1211 studies. However, most of these are trials are for long-term management of the disease; when ongoing trials for symptomatic MS treatments are searched the end result is discouraging. There are only a few dozen ongoing trials, with most of them being with already approved drugs in different indications and trials with novel drugs for symptomatic therapies in MS at almost none. Medications such as natalizumab, besides helping to prevent active MS, have also been shown to help with fatigue2, one of the most disabling symptoms of MS. However, this is a secondary effect rather than being a primary focus of the drug. In this example, it is clear that fatigue is a multifactorial problem in MS and blocking immune cells to the central nervous system (CNS) with a strong and risky medication to help only fatigue would not be sufficient justification to use natalizumab.
Why is the number of studies sponsored by the industry so disproportionally low compared with the ones going on for long-term treatments? There certainly is a need. Is it a matter of lack of interest? Is it the low expectancy of finding an effective drug? Or is it a matter of commercial expectations? We believe it is probably a combination of all of the above.
Many drugs are known to be effective in some MS symptoms but insufficiently so. We need better drugs for spasticity, ataxia, gait difficulties, tremors, sensory symptoms such as central neuropathic pain and other disturbing paresthesia, primary fatigue, bladder dysfunction, bowel problems-such as fecal incontinence and constipation-and sexual dysfunction. Most if not all treatments used in these symptoms in MS today are drugs that have been shown to have some effect for similar symptoms in non-MS neurologic disorders and by experience are used in MS care. Most such drugs A Siva and O Kantarci are prescribed in fact off-label and without well conducted clinical trials. One thing is their costs are low.
What are the symptomatic MS treatments introduced since the approval of the first MS disease-modifying treatment? Dalfampiridine for a modest effect on gait, 3,4 botulinium A-toxin for neurogenic bladder dysfunction 5, 6 and the synthetic cannabinoids for spasticity. 7, 8 All of these drugs offer some additional relief for some MS symptoms for which there were already other alternatives. One issue is that these drugs, although approved for MS symptoms, are not or will not remain limited to MS as these symptoms occur in many other neurologic disorders as well. For example, there are other indications reported for the use of dalfampiridine, such as Lambert Eaton Myasthenic syndrome, cerebellar gait disorders and nystagmus, motor neuron disease and some extrapyramidal diseases. 9 But their official approval will require proper trials. The use and indications for botulinum-A toxin for neurogenic detrusor overactivity and detrusor-sphincter dyssynergia is not limited only to MS, but has been approved for neurogenic bladder dysfunction secondary to spinal cord injuries and other related disorders. On the other hand, positive results with non-drug treatments, such as neuromodulation for neurogenic bladder dysfunction, 10, 11 remind us that symptomatic therapies will not be limited only to drugs. The market is certainly there and much larger than MS-related complications.
The response observed with these new drugs and techniques, as well as with some of the conventional symptomatic therapies, implicate that something better can be achieved with further research in this field too, necessitating the urgency to conduct more research and start new trials. There is very little basic science research regarding targeting the mechanisms of symptomatic MS therapy presented in large MS meetings and, when they are, the interest in these presentations is certainly not great, as is evident from the number of attendees.
Some drugs that are already in use such as amantadine for fatigue still do not have a well-understood mechanism. Would it not make sense to start with "deeper" support for research into the biology of these medication effects and hopefully understand mechanisms that can lend themselves to better drug development?
Other drugs, short of stimulants for fatigue in MS, have only marginal effects and the stimulants have long-term addiction problems.
We have no effective drug for cognitive involvement-only cognitive rehabilitation has been shown to have minor efficacy for as long as it is given. It becomes a major symptom for some people with MS for which we have nothing to offer.
Currently there are no effective medications for severe tremors, one of the most disturbing and incapacitating symptoms seen in MS. The introduction of deep brain stimulation has helped only a minority of MS patients with this symptom. Not all MS patients are candidates for this procedure and once implanted the efficacy may be temporary. The need for effective treatment is extreme. The development and use of this and other medical devices for symptom management emphasize the importance of research in this field of medicine, extending the research activities of the pharmaceutical industry to include high-technology medical device development.
There is the also the new, emerging field of neuroprosthetic development. 12, 13 Through this new technology paraplegic people who have spinal cord trauma or some other pathologies may walk some steps and gain partial bladder control with implanted spinal cord stimulators. Cortical electrodes may enable paralyzed people to use artificial limbs to a certain extent to assist with some functions. However, most of the centers focusing in these fields are university based or research foundations, rather than the industry. Indeed outside the specialty centers it is almost impossible to have access to these modalities. Could this be improved by further industry focus on such modalities where technology can be made affordable for the masses?
It is our impression that most of the industry has a limited understanding of this aspect of MS care, which lowers patients' quality of life by causing dysfunctions and discomfort and which, in fact, could be treated as well. The focus has always been around immunomodulation, which is relevant to long-term management and certainly is of the utmost importance. We believe this is also driven by a perception that academic MS physicians are less active in educating the industry about the great need in this area. There is a large market and clinical application for symptomatic MS treatment development. Yes, the industry should spend more time and effort to develop MS symptomatic therapies and should spend more time in developing and studying new drugs and devices for this purpose, working in close collaboration with academic MS neurologists.
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Symptomatic therapy in multiple sclerosis: Big pharma should do more -commentary Michael Hutchinson
Management of an increasing burden of symptoms is the main preoccupation both of people with multiple sclerosis (MS) and their health care providers. 1 One of the advantages of a multidisciplinary clinic is that the many diverse skills needed to address the complex needs of people with MS are available in one place and time. The difficulties that we face include (a) numerous, disparate symptoms in different organ systems, (b) limited therapeutic options, and (c) low-powered, poor-quality trials, often with qualitative subjective endpoints and few quantitative 'hard' outcome measures. There is the perception that the pharmaceutical industry is not interested in addressing this unmet need; there is more money in disease-modifying therapies (introduced or reintroduced older therapies modified in some way for the market). A recent paper and accompanying editorial in Neurology outlined clearly the burgeoning market in these therapies, especially in the United States (US). 2 Pharmaceutical companies could, with some justification, reply that bringing a new therapy to market, particularly a new molecule, is a hugely expensive and slow process with high risks of failure and financial loss. The companies could also point out that there are numerous drugs already available which could be repurposed for use in symptom management. They might also point out that academic neurologists should conduct better trials. In a recent survey of clinical trials. gov, there were a total of 1299 trials in MS, of these 55% were industry funded. 3 Despite that, overall I do not get the impression that the pharmaceutical companies are not pulling their weight in the field of symptomatic therapies. The usual scenario at present is that the pharmaceutical industry develops a new molecule (be it an anti-muscarinic, anticonvulsant or antidepressant); eventually it is shown to be effective in phase 3 studies and then its effects are studied in an MS population. Thus the MS population really benefits only after the drug has been proven in another clinic population (for example, a new antidepressant in patients with primary bipolar disorder).
Fampridine, however, a selective blocker of potassium channels, which restores saltatory conduction, was an old drug known to improve symptoms in a proportion of MS patients. In its new formulation, dalfampridine, it had a partial effect in about 30% of patients with walking difficulties in a clinical trial situation. 4 One difficulty with symptomatic therapies is that there can be a mismatch between the perceived benefit to the patient/client and the objective measurement by the doctor. In a real-world situation, onethird of the patients were found to have improved (by greater than 20%) in their walking speed at four weeks and only 16% by six months. However, using the Multiple Sclerosis Walking Scale-12 (MSWS-12), two-thirds (66%) of patients reported improvement at four weeks and 60% at six months. 5 This is one of the difficulties with the assessment of symptomatic therapies: The objective measurement (in this case the 25-foot timed walk test) showed only an improvement in one third of the patients at four weeks and in one sixth of patients at six months. The same patients, however, were reporting significant changes in a validated self-report measure (MSWS-12) in 60% of patients at six months. Thus, either there was a prolonged placebo effect (unlikely), or the MSWS-12 was measuring something that cannot be judged by the 25-foot walk test (more likely).
Three other symptoms prominent in MS include bladder symptoms, pain and fatigue. We are probably best at managing bladder symptoms in people with MS and reasonably good (working with a pain specialist unit) at managing pain; fatigue is the really difficult symptom which none of us feel we can manage adequately. In this case, I feel the problem is with the clinician. We academic neurologists need to address both the origins and pathophysiology of fatigue and develop reasonably objective measures of fatigue severity. Once we understand the patho-mechanisms of fatigue, then we can test appropriate therapies. One recent surprising report was the suggestion that vitamin D supplementation might alleviate fatigue; this needs to be replicated. 6 In summary, I do not think that the pharmaceutical industry is dragging its heels in this area. We need more collaborative neurologist-led clinical trial research into novel therapies for specific symptoms in MS, the most prevalent and most difficult to treat being that of fatigue.
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